L3VLUP
ProSign in

HROW · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HROWVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HROW
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterHROWVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 20211 holders, $4.5m30 holders, $12.7bn
Q3 20211 holders, $4.8m35 holders, $10.1bn
Q4 20211 holders, $4.6m28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 20221 holders, $4.0m25 holders, $18.1bn
Q3 20221 holders, $6.6m22 holders, $18.4bn
Q4 20221 holders, $7.6m28 holders, $18.4bn
Q1 20231 holders, $7.8m26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 2024none listed holders, n.a.31 holders, $29.8bn
Q2 2024none listed holders, n.a.29 holders, $33.4bn
Q3 2024none listed holders, n.a.27 holders, $33.5bn
Q4 20241 holders, $390k26 holders, $28.5bn
Q1 2025none listed holders, n.a.21 holders, $35.4bn
Q2 2025none listed holders, n.a.21 holders, $32.3bn
Q3 2025none listed holders, n.a.22 holders, $25.9bn
Q4 2025none listed holders, n.a.26 holders, $31.8bn
Q1 2026none listed holders, n.a.25 holders, $31.8bn
Q2 20261 holders, $14m26 holders, $34.6bn
HROW

Harrow Health Inc

Holders
0
Reported value
$0
Buyers
10
Sellers
9

Breadth +1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only HROW (0)

None.

Only VRTX (26)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →